Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $8.75.

Several equities research analysts recently weighed in on RANI shares. HC Wainwright reaffirmed a “buy” rating on shares of Rani Therapeutics in a report on Friday, August 21st. Wall Street Zen raised shares of Rani Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Canaccord Genuity Group restated a “buy” rating and set a $5.00 price target on shares of Rani Therapeutics in a research report on Wednesday, May 20th. Weiss Ratings lowered shares of Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Finally, Chardan Capital upgraded shares of Rani Therapeutics to a “strong-buy” rating in a report on Wednesday.

Insiders Place Their Bets

In other news, CEO Talat Imran bought 35,000 shares of the business’s stock in a transaction on Friday, July 17th. The stock was purchased at an average cost of $0.72 per share, for a total transaction of $25,200.00. Following the completion of the transaction, the chief executive officer directly owned 469,736 shares of the company’s stock, valued at approximately $338,209.92. This trade represents a 8.05% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 26.73% of the stock is owned by company insiders.

Institutional Trading of Rani Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RANI. Stonepine Capital Management LLC acquired a new position in Rani Therapeutics during the second quarter worth about $2,670,190,000. Almitas Capital LLC acquired a new stake in Rani Therapeutics in the 2nd quarter valued at about $7,111,000. Seven Fleet Capital Management LP acquired a new stake in Rani Therapeutics in the 2nd quarter valued at about $1,011,299,000. Bank of America Corp DE bought a new position in shares of Rani Therapeutics during the 2nd quarter valued at about $706,000. Finally, AWM Investment Company Inc. bought a new position in shares of Rani Therapeutics during the 2nd quarter valued at about $5,703,000. Institutional investors own 30.19% of the company’s stock.

Rani Therapeutics Price Performance

Shares of Rani Therapeutics stock opened at $0.84 on Friday. Rani Therapeutics has a 1-year low of $0.44 and a 1-year high of $3.87. The business’s fifty day moving average price is $0.78 and its two-hundred day moving average price is $0.95. The company has a market capitalization of $117.10 million, a P/E ratio of -3.11 and a beta of 0.78.

Rani Therapeutics (NASDAQ:RANI) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. The business had revenue of $1.71 million during the quarter, compared to the consensus estimate of $0.93 million. On average, research analysts expect that Rani Therapeutics will post -0.17 earnings per share for the current fiscal year.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.